Abstract
Background: Brain tumors are the most aggressive disease, and cancerous brain tumors are a
severe life-threatening condition. The tumor growth-induced curvature of the brain (mass
impact) can cause serious impairment or death as it develops in the cranium, displaces or
replaces the surrounding tissue. Tumors are believed to weaken the blood-brain barrier,
contributing in a great diversity vasculature known as the blood tumor barrier. Conventional
Magnetic Resonance Imaging has a range of drawbacks in the diagnosis of the most common
intracranial brain tumors, including tumor specification and identification of grade tumors.
Perfusion-Weighted Magnetic Resonance Imaging and Diffusion-Weighted Magnetic Resonance
Imaging introduce a slew of new parameters to conventional Magnetic Resonance Imaging, and
they can be used to visualize neovascularization, a characteristic of tumor progression.
Objective : To identify of efficiency and accuracy of perfusion magnetic resonance imaging and
evaluation of brain tumors
Material and Methods : One hundred and fifteen patients with histologically proven brain tumors
were examined by 1.5 Tesla PHILIPS MR System. For four months, patients who were referred
in an MRI assessment were included in this review. Conventional MRIs protocol, (axial T2WI
(TSE), Axial T1WI (FSE), axial T2-FLAIR WI, axial T1WI post contrast). Axial Diffusion
Weighted Image (DWI) MRI. PW-MRI protocol axial Fast Echo –Echo Planar Image (FE-EPI)
Neuro-T2* Perfusion Dynamic Contrast Enhancement agent (DCE-MRI), (Gadolinium(Gd)
contrast Magnevist).
Results and discussion: Magnetic Resonance Imaging in (10) patients (8.70%) revealed features
consistent with brain tumors (control cases), the brain has been evaluated by conventional
(protocol C). (105) patients (91.3%) underwent examination with Perfusion weighted magnetic
resonance imaging (p-MRIs) by (FE-EPI) Neuro-T2
* Perfusion (DCE-MRI) ( protocol P), and
Diffusion weighted magnetic resonance imaging (d-MRIs) by DWI and ADC value, (18) patients
(15.65%) with the anaplastic astrocytoma WHO grade (III), (17) patients (14.78%) with
metastatic brain tumors, (15) patients (13.04%) with non-recurrence of post-operative brain
tumors, (11) patients (9.57%) with high grade glioma, (10) patients (8.70%) with
craniopharyngioma, (9) patients (7.83%) with glioblastoma multiforme WHO grade IV, (9)
patients (7.83%) with low grade glioma, (8) patients (6.96 %) with meningioma, the
gemistocytic astrocytoma WHO grade(II) was the lowest diagnosed brain tumor (2.61%).
Conclusions: Perfusion MRI sequence, and Diffusion MRI sequence efficiency and accuracy in
evaluation of brain tumors.
(FULL ARTICLE LINK) Read more ...
2021
|
|
|
